Webinar presentations and recordings

Webinar | Heart Ventricular Progenitor Cell Therapy and Using Gottingen Minipigs for Development of Curative Cardiovascular Cell Therapies

Webinar | Heart Ventricular Progenitor Cell Therapy and Using Gottingen Minipigs for Development of Curative Cardiovascular Cell Therapies

Guest speaker: David Henry | AstraZeneca, UK (18 March 2024)

This presentation will provide an overview of the use of cells in curative treatments (highlighting the use of Heart Ventricular Progenitor Cells in heart failure) and considerations for monitoring outsourced studies supporting first time in human (FTIH) trials. This nonclinical model presents significant study design and practical challenges that need addressing to ensure successful xenogeneic engraftment following intra cardiac dosing in minipigs. In addition, the implementation of an appropriate immunosuppression regimen is essential for successful engraftment of cells, for which it is important to confirm procurement of co-medications, navigating the dosing of multiple drugs and monitoring/maintenance of exposure of the comedication. Therefore, an overview of study designs, immunosuppression, the challenges of intra-cardiac dosing cells and supporting animals with appropriate welfare practices will be discussed.

Watch recorded webinar
 

Web Academy | Göttingen Minipigs & Veterinary Management (Introductory Course)

Web Academy | Göttingen Minipigs & Veterinary Management (Introductory Course)

Lecturer: Maja Ramløse, DVM | Ellegaard Göttingen Minipigs, Denmark (4 March 2024)

In this Web Academy, we will touch upon the basics of Göttingen Minipigs' biology and behaviour. We will look into general animal welfare aspects tailored to Göttingen Minipigs, incl. acclimatisation, socialisation, and behavioral management. Last but not least we will cover the most basic clinical issues and treatments in Göttingen Minipigs.

About the lecturer: Maja Ramløse is specialised in biomedicine and is an experienced veterinarian, incl. more than 6 years of working with pigs for biomedical purposes. She is the main responsible for the health and welfare of all animals at Ellegaard Göttingen Minipigs, incl. the Culture of Care program.

Webinar | Practical use of Göttingen Minipigs in Wound Healing Studies

Webinar | Practical use of Göttingen Minipigs in Wound Healing Studies

Guest speakers: Mikkel Lykke and Gitte Jeppesen | Scantox, Denmark (18 December 2023)

This webinar aims to provide an integrated perspective on designing, conducting, and interpreting wound healing studies in minipigs. The webinar presents a unique opportunity to gain a holistic understanding of wound healing studies, from regulatory compliance and study design to detailed tissue analysis, equipping attendees with the knowledge and skills to understand the field of wound healing research.

First, "Regulatory Aspects When Planning a Wound Healing Study in Göttingen Minipigs," will focus on the critical regulatory aspects and ethical considerations unique to using Göttingen Minipigs in wound healing research. This part is key for researchers in understanding the legal and ethical framework surrounding minipig studies in wound healing. Following this, "How to Effectively Design, Plan, and Run a Wound Healing Study" offers practical insights into the strategic planning of wound healing research. It covers the essentials of designing effective studies, selecting methodologies, and executing research plans, thereby enhancing the quality and impact of wound healing studies. Finally, "How to Perform the Histopathological Assessment of Wound Healing Studies," delves into the microscopic examination of healed tissues. Attendees will hear about typical findings in histopathology, crucial for evaluating the healing process and the effectiveness of treatment modalities.

Watch recorded webinar
 

Webinar | Humanized Göttingen Minipigs for the toxicological testing of therapeutic antibodies

Webinar | Humanized Göttingen Minipigs for the toxicological testing of therapeutic antibodies

Guest speakers: Jerome Egli | F. Hoffmann-La Roche, Basel, Switzerland Tatiana Flisikowska | Technische Universität München Andy Makin | Andrew Makin Preclinical Consulting ApS (27 October 2022)

The safety and efficacy of most novel biologicals is evaluated in animal models. However, most human therapeutic antibodies trigger xenogeneic responses in wild-type animals and thus rapid clearance of the drugs, which makes in vivo testing of human antibodies challenging. Here we report the generation of Göttingen Minipigs carrying a mini-repertoire of human genes for the immunoglobulin heavy chains γ1 and γ4 and the immunoglobulin light chain κ. In line with observations in human patients, the genetically modified minipigs tolerated the clinically non-immunogenic IgG1κ-isotype monoclonal antibodies daratumumab and bevacizumab, and elicited antibodies against the checkpoint inhibitor atezolizumab and the engineered interleukin cergutuzumab amunaleukin. The humanized minipigs can facilitate the safety and efficacy testing of therapeutic antibodies.

Watch recorded webinar
 

Live Webinar | Why you should consider Göttingen Minipigs as your large animal model

Live Webinar | Why you should consider Göttingen Minipigs as your large animal model

Guest speaker: Susanne Mohr | Senior Toxicology Project Lead, F. Hoffmann-La Roche, Basel, Switzerland, 25 January 2022

Watch recorded webinar

Live Webinar | Why you should consider Göttingen Minipigs as your large animal model

Live Webinar | Why you should consider Göttingen Minipigs as your large animal model

Guest speaker: Steven Van Cruchten | Professor, Comparative Perinatal Development, University of Antwerp, Belgium, 25 January 2022

Watch recorded webinar

Live Webinar | Why you should consider Göttingen Minipigs as your large animal model

Live Webinar | Why you should consider Göttingen Minipigs as your large animal model

Guest speaker: Edward Marsden | Associate Director, ERT, DART & Juvenile Toxicology, Charles River Laboratories, Lyon, France, 25 January 2022

Watch recorded webinar

Webinar | Göttingen Minipigs - a new model for gut microbiome studies

Webinar | Göttingen Minipigs - a new model for gut microbiome studies

Guest speaker: Christian Kapel | University of Copenhagen (30 November 2021)

In 2021, a business/university consortium received funding from the Innovation Fund Denmark to develop translational animal models for inflammatory bowel disease in man. The focus will be on induction of intestinal inflammation and characterising the dynamics of the gut microbiome of various pre- and probiotic intervention.

The project combines two omnivore animal models (insects: Fast and inexpensive screening; Minipigs: Highly predictive) for preclinical research on pipeline formulations in biotech and pharma intended for microbiome stimulation and treatment of chronic intestinal disorder in humans.

In this presentation preliminary observation will be presented by Professor Christian Kapel, University of Copenhagen, Denmark.

Please find more information about the project on www.minigut.dk

Webinar | Refinements in Minipig Inhalation Toxicology

Webinar | Refinements in Minipig Inhalation Toxicology

Guest speaker: Alice McNamara | Labcorp, UK (26 October 2021)

Minipig inhalation is an emerging field in toxicology due to their homology to humans. In this webinar, Alice McNamara MRCVS from Labcorp will share how the Labcorp team has successfully completed several regulatory toxicology studies using this model, and have implemented multiple welfare refinements including:

• Training. Design of a bespoke positive reinforcement training protocol to acclimatise animals to staff, training them to walk in a harness to the dosing suite and then tolerate wearing a mask for up to 120 minutes/session.

• Physical environment. From 3D printing masks in a variety of sizes to give a comfortable fit and minimise dead space, to optimising the dosing suite for pig comfort with tactile, auditory and olfactory enrichment, the environment of the dosing suite allowed animals to calmly settle and even fall asleep during dosing procedures.

• Safety monitoring. The safety of the animals is paramount in any study, so capnography and visual scoring to monitor the animals continuously was employed.

Watch recorded webinar.

Webinar | Göttingen Minipigs and Xenotransplantation

Webinar | Göttingen Minipigs and Xenotransplantation

Guest speakers: Joachim Denner | Institute of Virology Free University Berlin, Germany (26 August 2021)

Xenotransplantation is under development in order to alleviate the shortage of human transplants. For numerous reasons, pigs are the best donor animals. However, the use of pig cells or organs may be associated with the transmission of zoonotic viruses. In this webinar, Dr. Joachim Denner, from Institute of Virology Free University Berlin in Germany, explains the extensive analysis of Göttingen Minipigs, which will be used for the treatment of human diabetes patients in Germany in near future. Using sensitive PCR-based and immunological methods, in some animals hepatitis E virus (HEV), porcine cytomegalovirus (PCMV), and porcine circovirus 2 (PCV2) were found. In addition, porcine endogenous retroviruses (PERV-A, -B, and -C) were found integrated in the genome of all Göttingen Minipigs. However, when islet cells from Göttingen Minipigs were transplanted into cynomolgus monkeys, no transmission of PERV and other porcine viruses was observed. Whereas HEV, PCMV, and PCV2 can be successfully eliminated by antiviral drugs, early weaning, or a vaccine, first experiments to inactivate PERVs using CRISPR/Cas have been reported.

Watch recorded webinar.

Webinar | Pig models for human nutrition research

Webinar | Pig models for human nutrition research

Guest speakers: Knud Erik Bach Knudsen, Helle Nygaard Lærke, and Mihai Curtasu | Aarhus University, Denmark (29 June 2021)

Pigs are of interest in human nutritional research because of similarities in the genome, anatomy, digestive physiology, and body size to humans. Pigs are therefore increasingly being used to understand the exact mechanisms behind the role in progression or prevention of disease. Like humans, pigs are omnivores, and in an experimental setting, they can be fed human-like energy dense diets high in refined carbohydrates and fat and low in dietary fiber. The domestic pig is relevant for studying digestion, bioconversion, and absorption of diet-derived metabolites, but for the metabolic response to dietary intervention in relation to obesity-related diseases, miniature pigs serve better models. In this webinar, Professor Knud Erik Bach Knudsen, Senior Scientist Helle Nygaard Lærke, and Postdoctoral Researcher Mihai Curtasu will present and discuss studies in conventional and Göttingen Minipigs on the effect of diet composition in obesity development and mitigation particularly emphasizing the role of the diet-microbiota interaction.

Watch recorded webinar.

Webinar | Inhalation therapy for heart failure with reduced ejection fraction in Göttingen Minipigs

Webinar | Inhalation therapy for heart failure with reduced ejection fraction in Göttingen Minipigs

Guest speaker: Alessio Alogna | Charité Universitätsmedizin Berlin, Germany (10 June 2021)

Peptide-based therapies are at the forefront of therapeutic innovations in the cardiovascular field. However, the lack of a non-invasive administration route to the heart represents a challenge for the translation of preclinical compounds into the clinical arena. Dr. Alessio Alogna, Clinician Scientist from Charité Universitätsmedizin Berlin, will give some insights into a proof-of-concept, translational study recently performed in Göttingen Minipigs by his research group. This study investigated the efficacy of a novel therapy based on inhalation of peptide-loaded biocompatible calcium phosphate nanoparticles in tachypacing-induced heart failure with reduced ejection fraction (HFrEF).

Watch recorded webinar.

Webinar | Application of Göttingen Minipigs biological material in In Vitro studies

Webinar | Application of Göttingen Minipigs biological material in In Vitro studies

Guest speakers: Julia Lodder-Gadaczek | LTS Lohmann Therapiesysteme AG, Germany; and Anette Sams Nielsen | Copenhagen University Hospital, Denmark (27 May 2021)

In this webinar Dr. Julia Lodder-Gadaczek, Head of Laboratory PhA skin lab at LTS Lohmann Therapiesysteme AG in Germany, and Anette Sams Nielsen, Senior Scientist at Copenhagen University Hospital in Denmark, will share and discuss their experiences using biological material from Göttingen Minipigs.

Julia Lodder-Gadaczek: For the development of a transdermal therapeutic system (TTS) in vitro permeation experiments are used as models for the penetration of a drug through the skin to the vesicular system. These experiments are necessary to generate information about the properties of a new formulation in terms of drug penetration, kinetic profile of permeation, and needed concentration levels of the drug.  The barrier in this model is normally built by skin and for the early development stage of a new TTS the skin of Göttingen Minipigs is a usefull model. In this webinar the principle of the experiment, the preparation of the skin and the advantages and potential risks of using Göttingen Minipigs skin as model for in vitro permeation trials will be discussed.

Anette Sams Nielsen: Minipigs are superior animal models for human health and diseases with cardiovascular anatomy and physiology similar to humans. Rodent models of neurovascular and endothelial regulation of vascular tone has been thoroughly studied in vivo and ex vivo and does not always offer good translation to sparse human vascular biopsies available from surgery and biopsies. The size of Göttingen Minipigs allows us to dissect sufficient artery segments for thorough characterization, pairing and comparison using a very limited number of animals (3R). The aim of the current study was to characterize regulation of vascular tone in Göttingen Minipigs by selected agonists for sympathetic, parasympathetic, sensory and endothelial pathways and to compare vasomotor responses of coronary, cerebral and peripheral arteries using myographs. We will share our data and discuss the scientific and practical issues of studying minipig and rodent vasomotor actions.

Watch recorded webinar.

Webinar | The use of Minipigs in juvenile toxicity testing

Webinar | The use of Minipigs in juvenile toxicity testing

Guest speaker: Bianca Feyen | Janssen, Belgium (28 April 2021)

Göttingen Minipigs have become popular as a non-rodent species in routine repeat dose safety testing during the last few years and is also a promising model for juvenile toxicity studies. For pediatric indications requiring juvenile toxicity testing, the rat is still the preferred species because it is the most convenient and widely studied species with extensive historical control data and well-established testing methods. However, for some drugs it might not be an appropriate model or regulatory agencies may request both rodent and non-rodent juvenile studies, for example in case of pediatric-only indications. The minipig represents good similarity to man in terms of many organ systems, including their post-natal development. The most common non-rodent species for juvenile studies is still the dog, but the minipig has many practical advantages over the dog and monkey. Due to the relevant recent use of minipigs in this field, only a limited number of studies have been conducted within each age category (with commencement of dosing at different ages) and therefore background data are limited. In this webinar, Bianca Feyen, Toxicologist at Janssen in Belgium, will discuss the advantages of using minipigs in juvenile toxicity testing and provide an overview of available background data.

Watch recorded webinar.

Webinar | Induction of prediabetes and diabetes in adult obese Göttingen Minipigs

Webinar | Induction of prediabetes and diabetes in adult obese Göttingen Minipigs

Guest speaker: Sietse-Jan Koopmans | Wageningen University & Research, The Netherlands (15 April 2021)

To follow the natural course of obese type 2 diabetes in an adult Göttingen Minipig model, the pig needs to become obese first and subsequently develop diabetes. Once insulin-resistant obesity is established in adult Göttingen Minipigs by ad libitum feeding of a high energy Western diet, diabetes should evolve after a certain period of time. The capacity of pancreatic beta-cells to produce sufficient insulin to compensate for insulin resistance becomes limited and, as a result, blood glucose concentrations increase. However, pigs do not easily develop (pre)diabetes spontaneously, at least not in the time frame of 1 or 2 years after the induction of severe obesity. To accelerate the development of diabetes in obese Göttingen Minipigs, streptozotocin can be used to chemically reduce the pancreatic beta-cell mass in order to elevate blood glucose concentrations. In this webinar, Sietse Jan Koopmans from Livestock Research at Wageningen University & Research in The Netherlands, will discuss various strategies to induce prediabetes and diabetes in adult obese Göttingen Minipigs by repeated intravenous administration of streptozotocin.

Watch recorded webinar.

Webinar | Imaging techniques for Göttingen Minipigs with PET, MRI, and CT

Webinar | Imaging techniques for Göttingen Minipigs with PET, MRI, and CT

Guest speaker: Aage Kristian Olsen Alstrup | Aarhus University Hospital, Denmark (16 March 2021)

Imaging has become widespread in preclinical research and techniques for scanning Göttingen Minipigs have also proved to be extremely relevant. In this webinar, Aage Kristian Olsen Alstrup, from Aarhus University Hospital in Denmark, reviews the possibilities of scanning Göttingen Minipigs using different techniques: PET (positron emission tomography), MRI (magnetic resonance imaging), and CT (computerized tomography) scanning. The advantages and challenges of each scanning modality will be assessed from a practical perspective and the importance of anesthesia, surgical techniques, placement of pigs in the scanner, monitoring, administration of tracers, and possible post scanning complications will be reviewed as well.

Watch recorded webinar.

Webinar | Drug metabolism in Göttingen Minipigs: Critical information for species selection in drug safety testing

Webinar | Drug metabolism in Göttingen Minipigs: Critical information for species selection in drug safety testing

Guest speaker: Steven Van Cruchten | University of Antwerp, Belgium (24 February 2021)

Safety pharmacology, toxicology and pharmacokinetic (PK) data are critical in drug development to provide safety and exposure information for the clinical studies. For optimal species selection in the nonclinical studies, metabolite profiling and plasma protein binding are key PK data to be considered. Metabolites can be investigated in several in vitro matrices, including hepatocytes, subcellular fractions of liver (microsomes, S9), recombinant enzymes, as well as in vivo. As all of these in vitro matrices, except recombinant enzymes, are commercially available for Göttingen Minipigs, it is surprising that this species is still not routinely included in the in vitro drug metabolism testing battery of most pharmaceutical companies. In this presentation, Steven Van Cruchten, Professor in Comparative Perinatal Development at the University of Antwerp, will focus on drug metabolism in adult and juvenile minipigs together with their relation to other non-rodent species and man.

Watch recorded webinar.

Webinar | Anticancer drug development comparison of toxicity in minipig and mouse

Webinar | Anticancer drug development comparison of toxicity in minipig and mouse

Guest speaker: Sally-Anne Reynolds | Sequani Ltd., UK (3 February 2021)

This presentation gives a brief overview of anti-cancer drug development and discusses how the selection of the most appropriate preclinical species can help in predicting safe but potentially efficacious clinical starting doses. Using data from recent toxicity studies in the mouse and minipig on a novel anti-cancer therapeutic, Sally-Anne Reynolds, Toxicology Manager at Sequani Limited, describes how results obtained from studies in minipigs appeared to better predict potential adverse effects in humans, in terms of the nature of the effects and the dose levels at which they occurred.

Watch recorded webinar.

Webinar | Hypersensitivity reactions to nano-biopharmaceuticals: Foundation of a minipig model

Webinar | Hypersensitivity reactions to nano-biopharmaceuticals: Foundation of a minipig model

Guest speaker: Janos Szebeni | SeroScience Ltd., Hungary (12 January 2021)

Acute hypersensitivity reactions to intravenously administered nano-biopharmaceuticals, also known as Infusion Reactions (IRs), are complex, innate immune reactions arising from a variable combination of complement (C) activation and triggering of pattern recognition receptors on allergy mediating cells. Pigs, due to the presence of intravascular macrophages in the microcirculation of their lungs, called PIM cells, provide a sensitive model for studying the most dangerous, occasionally life-threatening cardiovascular response leading to anaphylactoid shock and death. Janos Szebeni, CEO at SeroScience Ltd. in Hungary, presents highlights of the clinical and pharmaco-industrial relevance of this problem and discusses the benefits of pigs compared to other animals in consistently reproducing human symptoms. Beyond detailing the conditions, mechanism, and prevention of IRs clarified in domestic pigs, the presentation will give an account of experiments in Göttingen Minipigs that suggest their suitability as a model for drug-induced IRs with all advantages for regulatory standardization. Other focal points will include immunogenicity of nano-biopharmaceuticals and anti-PEG antibodies.

Watch recorded webinar.

Webinar | Development of a urinary tract infection animal model in Göttingen Minipigs

Webinar | Development of a urinary tract infection animal model in Göttingen Minipigs

Guest speakers: Jeffrey Fernandez and Jessica Henn | Janssen Research & Development, USA (3 December 2020)

Urinary tract infections (UTIs) remain an unmet medical need as E. coli is the leading cause of bacteremia in the elderly, often starting as a UTI. Rodent models are inadequate because of the volume and route of the bacterial inoculum used to start the infection. Jeffrey Fernandez, Senior Scientist and Jessica Henn, Associate Scientist at Janssen Research & Development, will share results of initial experiments that may suggest that Göttingen Minipigs could serve as a promising animal model to predict the efficacy of agents to fight UTIs.

Recording and presentation slides not available.

Webinar | Minipigs in translational immunosafety assessment

Webinar | Minipigs in translational immunosafety assessment

Guest speakers: Tina Rubic-Schneider and Michael Kammüller | Novartis Institutes for BioMedical Research, Switzerland (19 November 2020)

The challenge for immunosafety assessment remains the interpretation-uncertainty of changes of selected immunological endpoints when assessing immunocompetence and immune dysregulation. Minipigs have received attention as alternative species to dogs and Non-Human Primates in immunosafety assessment; and recent comparative immunological studies in Göttingen Minipigs with other species have investigated and broadened the translational value of minipigs as an animal model in drug safety evaluations. In this webinar, Tina Rubić-Schneider and Michael Kammüller, Novartis Institutes for BioMedical Research (NIBR), will discuss aspects of the translational significance of Göttingen Minipigs in immune-safety assessment.

Recording and presentation slides not available.

Webinar | Inhalation studies in minipigs

Webinar | Inhalation studies in minipigs

Guest speaker: Simon Moore | Covance, UK (20 October 2020)

There has been a slow uptake to use minipigs as an alternative second species for inhalation studies, which is in part due to technical challenges, but also the historical classes of test articles being used such as beta-agonists, corticosteroids, anti-muscarinic for asthma and COPD, where the dog has been the species of choice based on available background data. However, with ongoing focus and debate on second species selection actively requesting the industry to equally consider all species and in many ways especially minipigs, there is now greater support for the minipig to be used more frequently. Global Lead of Inhalation Sciences and Engineering, Simon Moore from Covance, will discuss this opportunity, which is further supported by evidence, where the inhalation delivery route is now being used for respiratory diseases such as cystic fibrosis and idiopathic pulmonary fibrosis with novel compound classes or re-purposing from other routes of administration. 

Watch recorded webinar.

Webinar | Optical coherence tomography (OCT) for ocular safety assessment in Göttingen Minipigs

Webinar | Optical coherence tomography (OCT) for ocular safety assessment in Göttingen Minipigs

Guest speaker: Nora Denk | F. Hoffmann-La Roche, Switzerland (29 September 2020)

Optical coherence tomography (OCT) has become a standard diagnostic tool in ophthalmology and has gained increasing importance also in preclinical ocular safety assessment. It is a non-invasive technique and provides real-time cross-sectional images of ocular structures. In this webinar, Dr. Nora Denk, Hoffmann - La Roche Ltd, will share current use of this technique and provide an outlook for ongoing and future developments and possibilities for ocular safety assessments in Göttingen Minipigs.

Recording not available.

Webinar | The pig as a large preclinical model for therapeutic human anti-cancer vaccine development

Webinar | The pig as a large preclinical model for therapeutic human anti-cancer vaccine development

Guest speaker: Gregers Jungersen | Statens Serum Institut, Denmark (10 September 2020)

New porcine experimental animal models, that are genetically engineered to develop spontaneous tumors upon injection of genetic triggers, offer exciting new opportunities to study different phases of cancer immunoediting in immunocompetent large animal hosts. Gregers Jungersen, Professor in Veterinary Vaccine Research at SSI in Copenhagen, will share findings from the immunological landscape of such tumors in “Oncopig” studies performed in collaboration with the University of Illinois and discuss how minipigs may be used to increase the success rate of preclinical studies in cancer research.

Recording not available.

Webinar | Göttingen Minipigs Genetics: Breed history, breeding strategies and genome analyses

Webinar | Göttingen Minipigs Genetics: Breed history, breeding strategies and genome analyses

Guest speaker: Christian Reimer | University of Göttingen, Germany (26 August 2020)

As presented in a recent publication, genomic analysis can be a powerful tool to manage inbreeding and breed integrity in a small population, such as Göttingen Minipigs. Christian Reimer, from the University of Göttingen, shares how breeding shaped Göttingen Minipigs and what genome analysis can tell us about its current state.

Watch recorded webinar.

Webinar | Characterisation of the porcine immune system with a focus on Göttingen Minipigs

Webinar | Characterisation of the porcine immune system with a focus on Göttingen Minipigs

Guest speakers: Armin Saalmüller and Clara Pernold | Institute of Immunology at VetMedUni Vienna, Austria (2 July 2020)

Göttingen Minipigs are widely used by pharmaceutical companies for the development of new medicines including toxicology studies and safety assessment, but the knowledge about their immune system is still scarce. Professor, Dr. Armin Saalmüller, Chair of the Institute of Immunology at VetMedUni Vienna, Austria, and PhD student, Clara Pernold, will in the Webinar provide insight into combining the existing knowledge about the porcine immune system with immunological questions relating to the use of Göttingen Minipigs in preclinical studies.

Recording not available.

Webinar | The role of Göttingen Minipigs in dermal drug development

Webinar | The role of Göttingen Minipigs in dermal drug development

Guest speaker: Andy Makin | Andy Makin Preclinical Consulting ApS, Denmark (16 June 2020)

For all drug development programmes, it is vital that the non-clinical studies are appropriately designed. This includes the correct choice of species, especially when the route of administration is specialised. In the case of dermal application of drugs, Göttingen Minipigs is the species of choice, and in this webinar, Andy Makin, who is experienced in this field will explain the background and the reasons for this.

Watch recorded webinar.

Webinar | Pain models in Göttingen Minipigs - bridging the gap between rodents and humans

Webinar | Pain models in Göttingen Minipigs - bridging the gap between rodents and humans

Guest speaker: Sigal Meilin | MD Biosciences, Israel (14 May 2020)

Traditional rodent models have contributed significantly to our understanding of pain and pain mechanisms, but improving the animal models in these studies has become critical for developing safe and effective pain therapies. Sigal Meilin, Chief Scientific Officer at MD Biosciences, will share learnings from their study on pain models in Göttingen Minipigs, and how this species can bridge knowledge from pain studies in rodents and humans.

Watch recorded webinar.

Webinar | Vascular access and implantation of catheters in Göttingen Minipigs

Webinar | Vascular access and implantation of catheters in Göttingen Minipigs

Guest speaker: Adrian Zeltner | Ellegaard Göttingen Minipigs A/S, Denmark (30 January 2020)

Vascular access is key for successful studies and in this webinar, Adrian Zeltner will review the different options, including newer developments. Adrian has many years of experience in placing various catheters and in teaching in the techniques. The technical guide available and the options for ordering pre-implanted animals will also be briefly outlined.

Watch recorded webinar.

Webinar | What's good to know when considering Göttingen Minipigs for juvenile toxicology studies?

Webinar | What's good to know when considering Göttingen Minipigs for juvenile toxicology studies?

Guest speaker: Edward Marsden | Charles River Laboratories, France (30 October 2019)

Juvenile animal studies are increasingly being used to support the development of paediatric medicines. Göttingen Minipigs are ideal in many ways for such studies and are specifically mentioned in the close-to-final ICH S11 guideline. Edward Marsden, who has many years of experience in the field, will share his experiences regarding optimizing such studies which are often quite complex.

Watch recorded webinar.

Webinar | Göttingen Minipigs in human relevant safety assessment - learnings from Roche (safety pharmacology and toxicology/pathology)

Webinar | Göttingen Minipigs in human relevant safety assessment - learnings from Roche (safety pharmacology and toxicology/pathology)

Guest speakers: Susanne Mohr, Andrea Greiter-Wilke, and Björn Jacobsen | F. Hoffmann-La Roche Ltd, Switzerland (13 June 2019)

The selection of the non-rodent species is very important when performing toxicology and safety pharmacology studies. In this webinar, three experienced researchers from Roche - Susanne Mohr, Andrea Greiter-Wilke, and Björn Jacobsen - will share their experiences, with a special focus on Göttingen Minipigs. The webinar includes a 40 min presentation followed by a Q&A session based on questions submitted “online” during the talk.

Recording not available.

Webinar | Background pathology in Göttingen Minipigs

Webinar | Background pathology in Göttingen Minipigs

Guest speaker: Sean McKeag | Covance Laboratories Ltd, UK (10 April 2019)

When performing toxicology studies, knowledge of the background pathology is extremely important and for Göttingen Minipigs much is known and has been published. Sean McKeag from Covance will present an overview, including what especially to be aware of, and give a status on the upcoming INHAND guidance document for standardized nomenclature.

Recording and presentation slides not available.